Vertex : EU Okays Casgevy For Sickle Cell Disease & Transfusion-Dependent Beta Thalassemia Treatment

(RTTNews) – The European Commission has granted conditional marketing authorization to Casgevy, a CRISPR/Cas9 gene-edited therapy. Casgevy is approved for the treatment of patients who are 12 years of age and older with severe sickle cell disease characterized by recurrent vaso-o